Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$829.84
-2.0%
$916.20
$547.61
$972.53
$788.68B0.423.05 million shs6.57 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$111.96
-1.1%
$125.25
$94.73
$148.15
$502.42B0.424.36 million shs8.45 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$72.54
+1.1%
$64.11
$9.32
$99.41
$8.00B14.37 million shs3.42 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-6.32%-6.21%-4.37%+1.74%+52.89%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.10%-2.13%-4.88%-14.57%+17.26%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-2.18%+18.81%+13.33%+31.29%+631.40%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8734 of 5 stars
3.43.00.84.02.91.73.1
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.3028 of 5 stars
3.45.01.70.02.50.03.1
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.1748 of 5 stars
3.52.00.04.72.52.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$1,009.0021.59% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.86
Moderate Buy$144.5029.06% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.09
Buy$108.6049.71% Upside

Current Analyst Ratings

Latest VKTX, LLY, and NVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/31/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$1,025.00 ➝ $975.00
10/31/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,150.00 ➝ $1,100.00
10/25/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1,060.00 ➝ $1,250.00
10/24/2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
10/17/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$1,100.00
10/17/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$160.00 ➝ $156.00
10/10/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1,000.00 ➝ $1,033.00
10/10/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
10/9/2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
10/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$1,025.00 ➝ $1,025.00
9/25/2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$138.00 ➝ $138.00
(Data available from 10/31/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$38.92B20.26$6.96 per share119.21$11.44 per share72.54
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$258.00B1.95$2.97 per share37.66$3.45 per share32.45
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$3.48 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$6.79102.2034.233.2418.86%67.52%12.76%2/4/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$12.15B$2.9238.3426.781.4834.86%87.43%28.01%11/6/2024 (Confirmed)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$85.89M-$0.93N/AN/AN/AN/A-12.73%-12.31%2/5/2025 (Estimated)

Latest VKTX, LLY, and NVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2024N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.91N/A-$0.91N/AN/AN/A  
10/30/2024Q3 24
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1.52$1.18-$0.34$1.29$12.09 billion$11.44 billion      
10/23/2024Q3 2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.24-$0.22+$0.02-$0.22N/AN/A    
8/8/2024Q2 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.64$3.92+$1.28$4.56$9.83 billion$11.30 billion
8/7/2024Q2 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.71$0.65-$0.06$0.65$9.91 billion$9.82 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.63%+15.15%76.58%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.720.64%+16.52%24.66%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest VKTX, LLY, and NVO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/28/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.300.58%11/15/202411/15/202412/10/2024
8/6/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.51260.7%8/16/20248/16/20248/26/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.74
1.11
0.87
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.46
0.94
0.75
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
36.47
36.47

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.41 million949.19 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
63,3704.49 billion4.48 billionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20110.27 million106.20 millionOptionable

VKTX, LLY, and NVO Headlines

Recent News About These Companies

Research Analysts Issue Forecasts for VKTX FY2024 Earnings
FY2024 Earnings Estimate for VKTX Issued By Leerink Partnrs
Viking Therapeutics (NASDAQ:VKTX) Rating Reiterated by HC Wainwright
William Blair Has Negative Outlook for VKTX FY2024 Earnings
Viking Therapeutics, Inc. stock logo
Research Analysts Set Expectations for VKTX FY2024 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines

Company Descriptions

Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Novo Nordisk A/S logo

Novo Nordisk A/S

NYSE:NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Viking Therapeutics logo

Viking Therapeutics

NASDAQ:VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.